TCGA-E2-A10F-01A-11R-A10J-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.440
- UV_RESPONSE_DN+0.370
- COMPLEMENT+0.360
- INFLAMMATORY_RESPONSE+0.360
- KRAS_SIGNALING_UP+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
- ANGIOGENESIS+0.350
- COAGULATION+0.340
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.480
- E2F_TARGETS-0.390
- MYC_TARGETS_V1-0.370
- MYC_TARGETS_V2-0.350
- MTORC1_SIGNALING-0.340
- G2M_CHECKPOINT-0.320
- DNA_REPAIR-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.280
- SPERMATOGENESIS-0.240
- CHOLESTEROL_HOMEOSTASIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.916 |
| 2 | C3N-02923 | — | cohortMD2 | 0.896 |
| 3 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.890 |
| 4 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.889 |
| 5 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.888 |
| 6 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.887 |
| 7 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.884 |
| 8 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.882 |
| 9 | MDT-AP-3277 | Med | Medulloblastoma | 0.878 |
| 10 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |